Should We Use PPAR Agonists to Reduce Cardiovascular Risk?

Table 2

Selected laboratory data from fibrate endpoint trials.

Mean baseline level (mg/dL (mmol/L))		Percent difference between treatment groups
Helsinki Heart [76]		Gemfibrozil versus placebo
		1 year	3 years	5 years
Total cholesterol	269 (6.98)	−11%	−10%	−9%
LDL	189 (4.90)	−11%	−10%	−9%
HDL	47 (1.22)	11%	10%	7%
Triglycerides	178 (2.01)	−39%	−37%	−33%
Non-HDL	222 (5.76)	−15%	−14%	−13%
VA-HIT [12]			Gemfibrozil versus placebo
			1 year
Total cholesterol	175 (4.53)		−4%
LDL	112 (2.90)		0%
HDL	32 (0.83)		6%
Triglycerides	160 (1.81)		−31%
BIP [10]			Bezafibrate versus placebo
			1 year
Total cholesterol	212 (5.49)		−5%
LDL	148 (3.83)		−7%
HDL	34.6 (0.90)		18%
Triglycerides	145 (1.64)		−21%
FIELD [11]		Fenofibrate versus placebo
		4 months		End-of-study
Total cholesterol	194 (5.04)	−11%		−7%
LDL	119 (3.07)	−12%		−6%
HDL	42.5 (1.10)	5%		1%
Triglycerides	172 (1.94)	−29%		−22%